- BA in Biology, Sonoma State University
- PhD in Genetics, Stanford University, Stanford, CA
- Postdoctoral training, Lawrence Berkeley National Laboratory, Berkeley, CA
Service, Awards, and Honors
- 2007 White House Presidential Early Career Award for Scientists and Engineers (PECASE)
- 2008 Genome Technology Magazine Award for “Tomorrow’s PIs”
- 2008- Co-Organizer, “Advances in Genome Biology & Technology (AGBT).” Marco Island, FL
- 2008- Scientific Advisory Board, Ontario Institute for Cancer Research (OICR)
- 2004-2010 Editorial Board, Genome Research
- 2006-2010 Permanent Member Genomics, Computational Biology and Technology (GCAT) Study Section, National Institutes of Health
- 2011- Board of Directors, The Genome Partnership (not-for-profit)
- 2011- Scientific Advisor to the NHGRI Sequencing Program
- 2012- American Heart Association (AHA), Western States Affiliate Research Committee Member
- 2013- Chair Research Oversight Committee, Genome Canada “Enhanced CARE for RARE Genetic Diseases in Canada”
- 2013- Co-Organizer “Systems Biology of Gene Regulation and Genome Editing”. Cold Spring Harbor Laboratory Asia. Suzhou, China
- 2013- Instructor Leena Peltonen School of Human Genomics, Sanger Center, England
- 2014- Member Research Oversight Committee McGill University Genome Quebec Innovation Center (MUGQIC)
- 2015- Co-Chair, “Advances in Genome Biology & Technology (AGBT): Precision Medicine.” Scottsdale, AR
- >100 Peer Review Publications (see Google Scholar).
In 2003, Dr. Pennacchio joined the DOE Joint Genome Institute and has focused on applying state-of-the-art molecular methods to address wide-ranging questions existing in biology. He holds a dual appointment as a Division Deputy at the DOE Joint Genome Institute and a Senior Scientist at Lawrence Berkeley National Laboratory. Dr. Pennacchio received his Ph.D in 1998 from the Department of Genetics at Stanford University where he uncovered the genetic cause of a rare form of human epilepsy and subsequently generated one of the first mouse models for this common neurological disorder. In 1999, he was named an Alexander Hollaender Distinguished Fellow where he identified a novel apolipoprotein (ApoA5) involved in human and mouse triglyceride metabolism.
Current research interests and ongoing projects:
- Defining the vast landscape of gene regulatory sequences in the human genome.
- Understanding how variation in regulatory sequences influences human disease/biology.
- Assessing and exploiting next generation sequencing technologies for applications in both the energy and health sectors.
- VISTA Enhancers